Clinical Trial Update: Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating ISM8207 in participants with advanced solid tumors or relapsed/refractory B-cell lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Solid Tumors

Drugs mentioned

• ISM8207

Snippet

Sponsor: InSilico Medicine Hong Kong Limited | Conditions: Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma | Phase 1 | Status: RECRUITING